...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Annals of Thoracic Medicine >Chronic obstructive pulmonary disease lost in translation: Why are the inhaled corticosteroids skeptics refusing to go?
【24h】

Chronic obstructive pulmonary disease lost in translation: Why are the inhaled corticosteroids skeptics refusing to go?

机译：慢性阻塞性肺疾病无法翻译：为什么吸入糖皮质激素的怀疑论者拒绝这样做？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A survey of pulmonologists attending a clinical meeting of the Saudi Thoracic Society found that only 55% of responders considered that inhaled corticosteroids (ICS) had a positive effect on quality of life in Chronic Obstructive Pulmonary Disease (COPD). Why the divergence of opinion when all the guidelines have concluded that ICS improve quality of life and produce significant bronchodilation? ICS unequivocally reduce the rate of exacerbations by a modest 20%, but this does not extend to serious exacerbations requiring hospitalization. Bronchodilatation with ICS is now documented to be restricted to some phenotypes of COPD. Withdrawal of ICS trials reported a modest decline of FEV 1 (<5%) in half the studies and no decline in the other half. In spite of the guidelines statements, there is no concurrence on whether ICS improve the quality of life and there is no conclusive evidence that the combination of long-acting ?2 agonists (LABA) with ICS is superior to LABA alone in that regard. The explanation for these inconclusive results may be related to the fact that COPD consists of three different phenotypes with divergent responses to LABA and ICS. Therapy tailored to phenotype is the future for COPD.
机译：参加沙特胸腔学会临床会议的肺病学家的一项调查发现，只有55％的应答者认为吸入糖皮质激素（ICS）对慢性阻塞性肺疾病（COPD）的生活质量具有积极影响。当所有指南均得出结论认为ICS改善生活质量并产生明显的支气管扩张作用时，为什么会有分歧？ ICS明确将病情加重率降低了20％，但这并未扩展到需要住院治疗的严重病情加重。现在已经证明，ICS的支气管扩张仅限于某些COPD表型。 ICS试验的撤出报告称，半数研究的FEV 1 轻微下降（<5％），而另一半则没有下降。尽管有指导性声明，但尚无关于ICS是否改善生活质量的共识，也没有确凿的证据表明长效β2激动剂（LABA）与ICS的结合在这方面优于LABA。对这些不确定性结果的解释可能与以下事实有关：COPD由三种不同的表型组成，对LABA和ICS的反应不同。适应表型的疗法是COPD的未来。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号